Journal
CURRENT MEDICINAL CHEMISTRY
Volume 19, Issue 23, Pages 3907-3921Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/092986712802002464
Keywords
Base excision repair (BER); BRCA1; BRCA2; CEP-9722; DNA repair; GPI-21016; INO-1001; iniparib; MK-4827; LT-673; olaparib; poly(ADP-ribose) polymerase (PARP) inhibitors; rucaparib; synthetic lethality; triple negative breast cancer; veliparib
Funding
- National Cancer Institute [P50-CA121973, U01-CA099168, P30-CA47904]
Ask authors/readers for more resources
Deeper understanding of DNA repair mechanisms and their potential value as therapeutic targets in oncology heralded the clinical development of poly(ADP-ribose) polymerase (PARP) inhibitors. Although initially developed to exploit synthetic lethality in models of cancer associated with defective DNA repair, our burgeoning knowledge of PARP biology has resulted in these agents being exploited both in cancer with select chemotherapeutic agents and in non-malignant diseases. In this review article, we briefly review the mechanisms of DNA repair and pre-clinical development of PARP inhibitors before discussing the clinical development of the various PARP inhibitors in depth.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available